Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) shares were down 7.2% during trading on Thursday . The stock traded as low as C$1.60 and last traded at C$1.60. Approximately 500 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 7,031 shares. The stock had previously closed at C$1.73.
Genscript Biotech Stock Up 18.8%
The firm has a fifty day moving average price of C$1.53 and a 200 day moving average price of C$1.77.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Further Reading
- Five stocks we like better than Genscript Biotech
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
